Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation

Journal of Internal Medicine

Volumn 260, Issue 4, 2006, Pages 363-368

  Tornvall, P ^a   Nilsson, T ^b   Lagerqvist, B ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Abciximab; PCI; STEMI

Indexed keywords

ABCIXIMAB;

ADULT; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; ST SEGMENT ELEVATION; STENT; SYSTEMATIC REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSTHESIS IMPLANTATION; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; RISK FACTORS; STENTS;

EID: 33748545337     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01696.x     Document Type: Article

References (17)

1. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26: 804-47.
2. De Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. A meta-analysis of randomized trials. JAMA 2005; 293: 1759-65.
3. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. J Am Coll Cardiol 2004; 44: 671-719.
4. Vidimsky P, Budesinsky T, Vorac D et al. Long distance transport for primary angoplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-Prague-2. Eur Heart J 2003; 24: 94-104.
5. Andersen HR, Nielsen TT, Rasmussen K et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-42.
6. Kandzari DE, Hasselblad V, Tcheng JE et al. Improved clinical outcomes with abciximab in acute myocardial infarction: a systemic overview of randomized trials. Am Heart J 2004; 147: 457-62.
7. de Queiroz Fernandes Araujo JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am Heart J 2004; 148: 937-43.
8. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903.
9. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
10. Antoniucci D, Rodriguez A, Hempel A et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879-89.
11. Antoniucci D, Migliorini A, Parodi G et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004; 109: 1704-6.
12. The ADMIRAL investigators. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur Heart J 2005; 26: 2520-3.
13. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915-21.
14. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292: 362-6.
15. Godicke J, Flather M, Noc M et al. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 2005; 150: 1015.
16. Huber K, De Caterina R, Kristensen SD et al. Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. Eur Heart J 2005; 26: 2063-74.
17. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297-300.